M A Tempero1, J Berlin2, M Ducreux3, D Haller4, P Harper5, D Khayat6, H-J Schmoll7, A Sobrero8, E Van Cutsem9. 1. Division of Hematology/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco. Electronic address: mtempero@medicine.ucsf.edu. 2. Division of Hematology/Oncology, Vanderbilt Ingram Cancer Center, Nashville, USA. 3. Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. 4. Department of Medicine, University of Pennsylvania Cancer Center, Philadelphia, USA. 5. Department of Medical Oncology, London Oncology Clinic, London, UK. 6. Department of Medical Oncology, Pitié-Salpêtrière Hospital, Paris, France. 7. Department of Internal Medicine IV, Hematology & Oncology, Univesitätsklinikum, Halle, Germany. 8. Department of Medical Oncology, Ospedale S. Martino, Genova, Italy. 9. Division of Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium.
Abstract
BACKGROUND: Pancreatic cancer has proven extremely challenging to treat. A collaborative effort is needed to advance research and improve treatment. An expert conference was conducted to elicit perspectives regarding the current treatment and future research of pancreatic cancer. METHODS: The conference comprised an international panel of experts representing five European countries and the United States. RESULTS: Adjuvant radiotherapy is used more frequently in the United States than in Europe. In locally advanced disease, there is now more emphasis on early chemotherapy in both Europe and the United States. In metastatic disease, combination chemotherapy is commonly used in Europe and the United States. This varies by country. Advancing pancreatic research will require improving biorepositories and developing a roadmap to prioritize therapeutic targets in different models. Small randomized phase II trials of both non-selected and enriched patient populations will help identify activity of new agents. Phase III trials should only be initiated in appropriate patients based on strong clinical and biological signals. Developing drugs in the adjuvant setting may be preferable to eliminate some of the challenges of drug development in the advanced disease setting. CONCLUSION: Progress in research combined with encouraging improvements from the past offer hope for the future of pancreatic cancer patients.
BACKGROUND:Pancreatic cancer has proven extremely challenging to treat. A collaborative effort is needed to advance research and improve treatment. An expert conference was conducted to elicit perspectives regarding the current treatment and future research of pancreatic cancer. METHODS: The conference comprised an international panel of experts representing five European countries and the United States. RESULTS: Adjuvant radiotherapy is used more frequently in the United States than in Europe. In locally advanced disease, there is now more emphasis on early chemotherapy in both Europe and the United States. In metastatic disease, combination chemotherapy is commonly used in Europe and the United States. This varies by country. Advancing pancreatic research will require improving biorepositories and developing a roadmap to prioritize therapeutic targets in different models. Small randomized phase II trials of both non-selected and enriched patient populations will help identify activity of new agents. Phase III trials should only be initiated in appropriate patients based on strong clinical and biological signals. Developing drugs in the adjuvant setting may be preferable to eliminate some of the challenges of drug development in the advanced disease setting. CONCLUSION: Progress in research combined with encouraging improvements from the past offer hope for the future of pancreatic cancerpatients.
Authors: Jun Zhao; Zhilan Xiao; Tingting Li; Huiqin Chen; Ying Yuan; Y Alan Wang; Cheng-Hui Hsiao; Diana S-L Chow; Willem W Overwijk; Chun Li Journal: ACS Nano Date: 2018-09-21 Impact factor: 15.881
Authors: Dana K Andersen; Åke Andren-Sandberg; Eric J Duell; Michael Goggins; Murray Korc; Gloria M Petersen; Jill P Smith; David C Whitcomb Journal: Pancreas Date: 2013-11 Impact factor: 3.327
Authors: Jun Zhao; Huamin Wang; Cheng-Hui Hsiao; Diana S-L Chow; Eugene J Koay; Yaan Kang; Xiaoxia Wen; Qian Huang; Ying Ma; James A Bankson; Stephen E Ullrich; Willem Overwijk; Anirban Maitra; David Piwnica-Worms; Jason B Fleming; Chun Li Journal: Biomaterials Date: 2018-01-09 Impact factor: 12.479
Authors: Christian Dittrich; Robert Königsberg; Martina Mittlböck; Klaus Geissler; Azra Sahmanovic-Hrgovcic; Johannes Pleiner-Duxneuner; Martin Czejka; Philipp Buchner Journal: Invest New Drugs Date: 2018-07-12 Impact factor: 3.850
Authors: Andreas-Claudius Hoffmann; Eray Goekkurt; Peter V Danenberg; Sylvia Lehmann; Gerhard Ehninger; Daniela E Aust; Jan Stoehlmacher-Williams Journal: PLoS One Date: 2013-05-21 Impact factor: 3.240